



CORPORATE PRESENTATION

JANUARY 2018

12538 West Atlantic Blvd.
Coral Springs, FL 33071 USA

Nutra Pharma is traded under the symbol: NPHC

Phone: (954) 509-0911

Fax: (877) 895-5647

investor.relations@NutraPharma.com

www.NutraPharma.com



COMPANY OVERVIEW

Nutra Pharma is a biotechnology company with a line of revenue-producing OTC pain drugs, which offset the expenses of clinical studies as the company pursues regulatory approval for its potentially blockbuster drugs for multiple sclerosis and HIV.



DUAL APPROACH

Nutra Pharma is focused on two areas:

Therapeutics in autoimmune, HIV and pain initial research; focused on two distinct therapeutic products for autoimmune diseases and HIV.

Over The Counter (“OTC”) chronic pain relievers (Nyloxin® and Pet Pain-Away™) currently being sold online and through distributors.

Dual approach minimizes risk to investors:

The currently marketed OTC products allow the firm to achieve profitability and fund longer-term clinical trials in the therapeutic area. Research will be conducted on multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain and others with the goal of early licensing to big pharma that will result in up-front and milestone payments as well as back-end royalties upon approval and marketing.

Nutra Pharma has mediated the risk to investors by creating revenue streams from its OTC drugs, as well as thoroughly testing its therapeutics prior to phase II trials.

DUAL APPROACH (CONTINUED)

Market strategy:

Nutra Pharma's OTC products allow the company to achieve profitability and fund longer-term clinical trials in the therapeutic area. The therapeutics address a market size of > \$10 billion, while the OTC products address a market size of \$200 million - \$500 million.

What Nutra Pharma intends to achieve over the next 5 years:

- Expanded retail sales of OTC products
- Continue pre-clinical work on first two therapeutic products
- Continue toward profitability within the next 12 months

INVESTMENT HIGHLIGHTS

Nutra Pharma has established an extensive intellectual property (IP) portfolio, which serves as the foundation of the company's achievements to-date.

As of January 2018, Nutra Pharma has:

- 21 patents and 6 published studies and review articles
- 12 Registered OTC products with the U.S.-FDA
 - 7 SKUs of Nyloxin; 2 SKUs of Nyloxin Military Strength; 2 SKUs of Cobroxin; 1 SKU of Pet Pain-Away
 - Approval of Nyloxin in India
- 2 completed trials in adrenomyeloneuropathy (AMN)
- 1 completed trial in HIV
- 300+ patients on open-label use with multiple sclerosis (MS)
- Received Orphan Designation from the U.S.-FDA for RPI-78M as a candidate for the treatment of juvenile MS



THERAPEUTIC PIPELINE

Supplemented by revenue streams from its OTC pain drugs, Nutra Pharma is aggressively advancing its therapeutic pipeline of potentially blockbuster drugs toward regulatory approval.



DRUG DISCOVERY

Nutra Pharma's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain.

RPI-78M

Indication	PC	P-I	P-II	P-III
Multiple Sclerosis				
Herpes Simplex Infections 1 & 2				
Adrenomyeloneuropathy				
Adrenomyeloneuropathy (Oral)				

RPI-78

Indication	PC	P-I	P-II	P-III
Rheumatoid Arthritis				
Pain				

RPI-MN

Indication	PC	P-I	P-II	P-III
Human Immunodeficiency Virus (Oral)				
Human Immunodeficiency Virus				
Amyotrophic Lateral Sclerosis				
Herpes Simplex Keratitis				

Planning	
In Progress	
Completed	

BACKGROUND RPI-78M

RPI-78M is derived from alpha-cobratoxin (α -CTX) by an oxidative procedure.

Alpha-cobratoxin is the primary neuroactive peptide found in the venom of Asiatic cobras, and it represents the single active ingredient in the formulation under investigation. This is a registered, homeopathic product that allows for the specific health claims made on the product and availability as an over-the counter (OTC) drug.



3-dimensional structure of
alpha-cobratoxin

RPI-78M has an excellent safety record over years of use in human studies; detoxified cobratoxin has not revealed any measurable toxicity. Injections of 5g/Kg into mice (650,000 times a human dose wt/wt) reveal no adverse effects, and in numerous preclinical studies no animals have ever died from RPI-78M administration even when given intracerebrally. Preliminary human clinical investigations with RPI-78M also revealed no significant concerns.

When compared to other biologic drugs, RPI-78M possesses several desirable properties, including:

- Lacks measurable toxicity, but is still capable of attaching to and affecting the target site on the cells. This means that patients cannot overdose.
- Displays no serious adverse side effects following years of investigations in humans and animals.
- Patients experience symptomatic improvements, usually within 6 months of therapy
- Extremely stable and resistant to heat, which gives the drugs a long shelf life. The drug's stability has been determined to be over 4 years at room temperature.
- Easy to administer as a daily intramuscular injection (mcg dosing).

NUTRA PHARMA ACCOMPLISHMENTS WITH RPI-78M

Pre-Clinical:

Pharmacodynamics
Pharmacokinetics
Micro-Array

Toxicity:

Mice
Rats
Rabbits
Cats
Dogs

Animal Models:

Experimental allergic encephalomyelitis (EAE) in guinea pigs
Experimental allergic encephalomyelitis (EAE) in female Lewis rats
Adjuvant-induced arthritis (AIA) in rats

Key Intellectual Property

U.S. Patent No. 8,034,777	Modified Anticholinergic Neurotoxins as Modulators of the Autoimmune Reaction
U.S. Patent No. 7,902,152	Use of cobratoxin as an analgesic
U.S. Patent No. 7,758,894	Modified elapid venoms as stimulators of the immune reaction

NUTRA PHARMA's RPI-78M THERAPY FOR AUTO-IMMUNE DISEASES

***RPI-78M* under Orphan Designation for the Treatment of Juvenile Multiple Sclerosis (MS)**

Nutra Pharma is actively seeking collaborative research partners for early stage trials of RPI-78M in the treatment of juvenile multiple sclerosis (MS).

The Company has already been in contact with potential researchers, hospitals and sites of care for the purpose of moving forward with phase I/II clinical studies.

Nutra Pharma believes that RPI-78M provides an entirely new approach to the treatment of auto-immune diseases, including MS. As an immuno-modulating agent and NOT an immunosuppressive, RPI-78M could be a disruptive new drug entity in the autoimmune disease space.

In previous open-label studies, RPI-78M has shown consistent symptomatic improvements within a period of less than six months in all stages of MS.

RPI-78M has received Orphan Drug designation from the U.S.-FDA, allowing the Company to fast-track efforts through the clinical process and eventual approval in the indication.

Based on existing clinical experience with RPI-78M, Nutra Pharma is confident that it can receive accelerated approval in a relatively short time-frame (expected in as little as 22-26 months).



NUTRA PHARMA OTC PRODUCTS

Nutra Pharma markets a line of OTC products for the treatment of chronic pain under the brands Nyloxin® and Pet Pain-Away™.



THE PROBLEM OF PAIN

Nyloxin

Chronic Pain Relief

Pain is the single most common reason patients seek medical care and accounts for half of all physician office visits in the United States.

According to the American Pain Foundation, each year more than 25 million people in the United States experience acute pain as a result of injury or surgery. Additionally, more than 50 million Americans are affected by ongoing chronic pain.

Nutra Pharma's Nyloxin:

1. Makes potent pain relief accessible to:
 - People without healthcare insurance (42 million)
 - People without prescription coverage
 - People afraid of opiate side effects
 - People subject to drug screening for work
 - People for whom OTC NSAIDs didn't work and are just living with pain
 - Doctors afraid to prescribe opiates
2. Target consumers not well-served by current products on the market

NYLOXIN OVERVIEW



Nyloxin[®] is available as an over-the-counter (OTC) pain reliever clinically proven to treat Stage 2 (moderate to severe) and Stage 3 (severe) chronic pain. **Safe, non-narcotic** and **non-addictive**, Nyloxin does not impair cognitive function.

Nyloxin was launched in mid-2011 as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia, and as topical gel for treating joint pain, arthritis pain and pain from repetitive stress.




Nyloxin is available in both everyday strength and extra strength.

NYLOXIN ADVANTAGE

Nyloxin

Chronic Pain Relief



NYLOXIN ADVANTAGE

NYLOXIN DISTRIBUTUION



Nyloxin® is currently being distributed in physician offices, small chain pharmacies as well as on-line through www.Nyloxin.com and on Amazon.

Nyloxin is available through the company's website at www.Nyloxin.com as well as other online retailers.

Nyloxin is also sold through physician offices and small chain pharmacies throughout the United States.

Nutra Pharma is approved to distribute Nyloxin in India and is currently negotiating with large distributors throughout the region. Nutra Pharma is also working with several potential distributors in Canada, China and Australia with the expectation to complete international registrations by late 2018.

NEW & FUTURE PRODUCTS

Pet Pain-Away provides pain relief for companion animals. The product began shipping in December 2014. Pet Pain-Away is all natural, non-addictive, non-opiate, NSAID-free, and made in a hypoallergenic chicken flavor that dogs and cats LOVE!



New additions will also include:

Nyloxin® Tablets

Nyloxin® Military Strength – For U.S. government buyers and active duty military

Luxury Feet – for women who experience pain when wearing high heels

PET PAIN-AWAY MARKET

Pets Owned in the U.S.: 95.6 million cats, 83.3 million dogs

Pet Pain-Away™
ALL NATURAL
Chronic Pain Relief for Dogs and Cats

- ★ Pain from Hip Dysplasia
- ★ Arthritis Pain & Joint Pain
- ★ General Chronic Pain

Take the pain away for your best friend.

NET WT 20g

The market for pain relief in dogs and cats is more than \$200 million.

Pet Pain-Away is available online at www.petpainaway.com as well as specialty pet stores and veterinary offices

NUTRA PHARMA
CORPORATION

MARKET SIZE - OVERVIEW

Market Values

OTC Chronic Pain

- ~100 million Americans
- \$2B in annual sales
- Alternative products (i.e. Nyloxin) could generate over \$500M annually

Pet Pain

- 95.6 million cats, 83.3 million dogs in the U.S.
- OTC pain category in companion animals is >\$200M annually

Human Immunodeficiency Virus (HIV)

- 34.2 million people are HIV positive
- 1.2 million people are infected each year
- 56,300 Americans become infected each year
- \$15.1 billion annual drug market

Multiple Sclerosis (MS)

- 2.5 million people diagnosed with MS
- 400,000 sufferers in the United States
- \$16.7 billion annual drug market

Adrenomyeloneuropathy (AMN)

- AMN/ALD affects an estimated 30,000 people in the U.S.
- No therapeutics, so no known market size. Estimated at \$400M+

MANAGEMENT TEAM

Experienced Management Team

Focused on the OTC chronic pain relief market and in select therapeutic areas.

Rik J. Deitsch - Chairman and Chief Executive Officer

Rik Deitsch holds both a B.S. in chemistry and an M.S. in biochemistry, and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic. Deitsch is the author of two books and is an adjunct professor, teaching several courses for Florida Atlantic University's College of Business and Continuing Education Department.

Stewart Lonky, MD MBA - Director - Audit & Compensation Committees

Stewart Lonky is board certified in internal medicine, pulmonary and critical care medicine. He has published over a dozen articles in the peer-reviewed literature. Former chief medical officer of a medical device company that developed diagnostic products for the early diagnosis of cervical and oral cancer. In that role, his duties included the direction of clinical research and the ultimate clearance of three new diagnostic devices by the U.S. Food and Drug Administration (FDA).

Harold H. Rump - Director

Harold Rump holds a B.S. from the United States Naval Academy. He is the former president, and director of Biogenix, Inc., a company involved with research and development of antiviral peptides from cobra venoms, including clinical trials under FDA-issued Investigational New Drug applications.

Garry R. Pottruck, CPA - Director - Chairman, Audit & Compensation Committees

Garry Pottruck is a CPA and financial expert on the NPHC's board of directors. Previously he served as chief accounting officer/controller at Scopas Technology Company, Inc., a NASDAQ-listed, development stage biotechnology research and development organization; and principal and manager in the firm Argy, Wiltse & Robinson, PC ("Argy"), headquartered in McLean, Virginia.

SUMMARY

IN SUMMARY

- Nutra Pharma is expanding its OTC retail sales marketing program and preparing clinical development of its first two therapeutic products.
- Nutra Pharma has a highly experienced management team in place with the experience necessary to successfully achieve its targeted milestones quickly.
- Nutra Pharma is focused on reaching profitability and maximizing shareholder return on investment.
- Orphan Drug Status for RPI-78M greatly reduces the costs and timeline to move into clinical studies and create licensing partnerships
- Currently, Nutra Pharma is trading at all-time lows while the company has: reduced debt, increased sales and restarted laboratory operations. All of these things will show increasing value in the near term.

FOR MORE INFORMATION

For more information, please visit:

www.NutraPharma.com

Stock Symbol: NPHC

Distributor websites:

www.Nyloxin.com

www.PetPainAway.com

CONTACT:

Rik J Deitsch
Chief Executive Officer
Office: 954-509-0911
Fax: 877-895-5647

Rik.Deitsch@nutrapharma.com

